These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22227590)

  • 1. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
    Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
    Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
    Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion.
    Kleinclauss F; Perruche S; Masson E; de Carvalho Bittencourt M; Biichle S; Remy-Martin JP; Ferrand C; Martin M; Bittard H; Chalopin JM; Seilles E; Tiberghien P; Saas P
    Cell Death Differ; 2006 Jan; 13(1):41-52. PubMed ID: 15962005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
    Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
    Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis.
    Sagiv Y; Kaminitz A; Lorberboum-Galski H; Askenasy N; Yarkoni S
    Ann N Y Acad Sci; 2009 Sep; 1173():791-7. PubMed ID: 19758230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
    Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
    Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
    Xia G; Kovochich M; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
    Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
    Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
    Giorgini A; Noble A
    J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
    Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
    J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice.
    Stark J; Weiss L; Slavin S
    Isr J Med Sci; 1992 Nov; 28(11):767-72. PubMed ID: 1468887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
    Hashimoto D; Asakura S; Matsuoka K; Sakoda Y; Koyama M; Aoyama K; Tanimoto M; Teshima T
    Eur J Immunol; 2007 Jan; 37(1):271-81. PubMed ID: 17154260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.